+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis



Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis



Canadian Journal of Gastroenterology 21(4): 217-222



To assess the cost-effectiveness of photodynamic therapy (PDT) and esophagectomy (ESO) relative to surveillance (SURV) for patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD). A Markov decision tree was constructed to estimate costs and health outcomes of PDT, ESO and SURV in a hypothetical cohort of male patients, 50 years of age, with BE and HGD. Outcomes included unadjusted life-years (LYs) and quality-adjusted LYs (QALYs). Direct medical costs (2003 CDN$) were measured from the perspective of a provincial ministry of health. The time horizon for the model was five years (cycle length three months), and costs and outcomes were discounted at 3%. Model parameters were assigned unique distributions, and a probabilistic analysis with 10,000 Monte Carlo simulations was performed. SURV was the least costly strategy, followed by PDT and ESO, but SURV was also the least effective. In terms of LYs, the incremental cost-effectiveness ratios were 814 dollars/LY for PDT versus SURV and 3,397 dollars/LY for ESO versus PDT. PDT dominated ESO for QALYs in the base-case. The incremental cost-effectiveness ratio of PDT versus SURV was 879 dollars/QALY. In probabilistic analysis, PDT was most likely to be cost-effective at willingness-to-pay (WTP) values between 100 dollars/LY and 3,500 dollars/LY, and ESO was most likely to be cost-effective for WTP values over 3500 dollars/LY. For quality-adjusted survival, PDT was most likely to be cost-effective for all WTP thresholds above 1,000 dollars/QALY. The likelihood that PDT was the most cost-effective strategy reached 0.99 at a WTP ceiling of 25,000 dollars/QALY. In male patients with BE and HGD, PDT and ESO are cost-effective alternatives to SURV.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054983296

Download citation: RISBibTeXText

PMID: 17431509

DOI: 10.1155/2007/791062


Related references

Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 60(5): 739-756, 2004

Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Digestive Diseases & Sciences 48(7): 1273-1283, 2003

Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus. Journal of Comparative Effectiveness Research 6(5): 425-436, 2017

Cost effectiveness analysis of photodynamic therapy for treatment of high grade dysplasia in barretts esophagus. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 319, 2003

Photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Comprehensive Therapy 31(2): 137-144, 2005

An Educational Tool for Photodynamic Therapy of Barrett Esophagus With High-Grade Dysplasia. Gastroenterology Nursing 28(5): 413-419, 2005

Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Journal of Clinical Gastroenterology 39(3): 189-202, 2005

Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 65(1): 60-66, 2007

Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia. Lasers in Surgery and Medicine 38(5): 390-395, 2006

An educational tool for photodynamic therapy of Barrett esophagus with high-grade dysplasia: from screening through follow-up. Gastroenterology Nursing 28(5): 413-9; Quiz 420-1, 2005

Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 136(1): 56-64; Quiz 351-2, 2009

Eradication of high-grade dysplasia in Barrett esophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Zeitschrift für Gastroenterologie 36(1): 111-113, 1998

Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey. Gastroenterology Nursing 25(4): 139-141, 2002

Radiofrequency ablation is effective for the treatment of high-grade dysplasia in Barrett's esophagus after failed photodynamic therapy. Endoscopy 43(7): 627-630, 2012

Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia. Clinical Cancer Research 15(5): 1830-1836, 2009